Christopher R. Cline net worth and biography

Christopher Cline Biography and Net Worth

Chief Financial Officer of Travere Therapeutics

Chris Cline, CFA, serves as the chief financial officer and member of the executive team at Travere Therapeutics. He is responsible for overseeing the company’s corporate and strategic finance, and investor relations activities. Mr. Cline brings more than 15 years of industry experience in investor relations, corporate communications, and financial strategy, planning and analysis to the chief financial officer position. Previously, Mr. Cline served as senior vice president, investor relations and corporate communications at Travere. Since joining Travere in 2014, Mr. Cline has been responsible for leading engagement with the investment community, as well as building a developed corporate communications infrastructure and strategy. Prior to Travere, Mr. Cline was a member of the global investor relations group at Elan Corporation, plc, and the financial planning and analysis group at Phase Forward. Mr. Cline is a CFA charter holder and holds a degree in finance from the Williams College of Business at Xavier University.

What is Christopher R. Cline's net worth?: The estimated net worth of Christopher R. Cline is at least $1.78 million as of February 3rd, 2025. Mr. Cline owns 90,038 shares of Travere Therapeutics stock worth more than $1,776,450 as of March 15th. This net worth approximation does not reflect any other investments that Mr. Cline may own. Additionally, Mr. Cline receives an annual salary of $709,940.00 as Chief Financial Officer at Travere Therapeutics. Learn More about Christopher R. Cline's net worth.
How old is Christopher R. Cline?: Mr. Cline is currently 39 years old. There are 5 older executives and no younger executives at Travere Therapeutics. The oldest executive at Travere Therapeutics is Dr. William E. Rote Ph.D., Senior VP and Head of Research & Development, who is 61 years old. Learn More on Christopher R. Cline's age.
What is Christopher R. Cline's salary?: As the Chief Financial Officer of Travere Therapeutics, Inc., Mr. Cline earns $709,940.00 per year. There are 4 executives that earn more than Mr. Cline. The highest earning executive at Travere Therapeutics is Dr. Eric M. Dube Ph.D., President, CEO & Director, who commands a salary of $1,400,000.00 per year. Learn More on Christopher R. Cline's salary.
How do I contact Christopher R. Cline?: The corporate mailing address for Mr. Cline and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at ir@retrophin.com. Learn More on Christopher R. Cline's contact information.
Has Christopher R. Cline been buying or selling shares of Travere Therapeutics?: In the last ninety days, Christopher R. Cline has sold $120,846.14 of Travere Therapeutics stock. Most recently, Christopher R. Cline sold 5,192 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a transaction totalling $104,463.04. Following the completion of the sale, the chief financial officer now directly owns 90,038 shares of the company's stock, valued at $1,811,564.56. Learn More on Christopher R. Cline's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Roy Baynes (Director), Sandra Calvin (CAO), Laura Clague (CFO), Christopher Cline (Chief Financial Officer), Eric Dube (CEO), Peter Heerma (Insider), Jula Inrig (Insider), Gary Lyons (Director), Jeffrey Meckler (Director), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 28 times. They sold a total of 329,186 shares worth more than $6,178,934.13. The most recent insider tranaction occured on February, 12th when SVP William E Rote sold 5,200 shares worth more than $122,356.00. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 2/12/2025.

Christopher R. Cline Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/3/2025	Sell	5,192	$20.12	$104,463.04	90,038
1/22/2025	Sell	865	$18.94	$16,383.10	73,730
9/9/2024	Sell	2,490	$11.52	$28,684.80	74,595
9/4/2024	Sell	514	$9.51	$4,888.14	70,335
4/11/2024	Sell	54	$6.74	$363.96	70,849
2/1/2024	Sell	3,818	$8.53	$32,567.54	70,903
1/23/2024	Sell	853	$9.07	$7,736.71	49,721
9/5/2023	Sell	457	$14.71	$6,722.47	50,574
5/10/2023	Sell	455	$16.59	$7,548.45	51,031
4/11/2023	Sell	47	$21.49	$1,010.03	51,486
2/1/2023	Sell	1,588	$21.75	$34,539.00	51,533
1/24/2023	Sell	852	$21.90	$18,658.80	32,871

Christopher R. Cline Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $19.73

$18.86

$19.87

50 Day Range

MA: $20.33

$17.07

$23.75

2 Week Range

Now: $19.73

$5.12

$25.29

Volume

1,137,210 shs

Average Volume

1,411,373 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Christopher Cline Biography and Net Worth

What is Christopher R. Cline's net worth?

How old is Christopher R. Cline?

What is Christopher R. Cline's salary?

How do I contact Christopher R. Cline?

Has Christopher R. Cline been buying or selling shares of Travere Therapeutics?

Who are Travere Therapeutics' active insiders?

Are insiders buying or selling shares of Travere Therapeutics?